|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valeri N, Gasparini P, Fabbri M, Braconi
C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, et
al: Modulation of mismatch repair and genomic stability by miR-155.
Proc Natl Acad Sci USA. 107:pp. 6982–6987. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Geng L, Chaudhuri A, Talmon G, Wisecarver
JL, Are C..Brattain M and Wang J: MicroRNA-192 suppresses liver
metastasis of colon cancer. Oncogene. 33:5332–5340. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eker B, Ozaslan E, Karaca H, Berk V,
Bozkurt O, Inanc M, Duran AO and Ozkan M: Factors affecting
prognosis in metastatic colorectal cancer patients. Asian Pac J
Cancer Prev. 16:3015–3021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ozawa T, Kandimalla R, Gao F, Nozawa H,
Hata K, Nagata H, Okada S, Izumi D, Baba H, Fleshman J, et al: A
microrna signature associated with metastasis of T1 colorectal
tumors to lymph nodes. Gastroenterology. Nov 30–2017. View Article : Google Scholar
|
|
6
|
Bu P, Wang L, Chen KY, Srinivasan T,
Murthy PK, Tung KL, Varanko AK, Chen HJ, Ai Y, King S, et al: A
miR-34a-numb feedforward loop triggered by inflammation regulates
asymmetric stem cell division in intestine and colon cancer. Cell
Stem Cell. 18:189–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hur K, Toiyama Y, Okugawa Y, Ide S, Imaoka
H, Boland CR and Goel A: Circulating microRNA-203 predicts
prognosis and metastasis in human colorectal cancer. Gut.
66:654–665. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang L, Cai M, Gong Z, Zhang B, Li Y,
Guan L, Hou X, Li Q, Liu G, Xue Z, et al: Geminin facilitates FoxO3
deacetylation to promote breast cancer cell metastasis. J Clin
Invest. 127:2159–2175. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guan L, Zhang L, Gong Z, Hou X, Xu Y, Feng
X, Wang H and You H: FoxO3 inactivation promotes human
cholangiocarcinoma tumorigenesis and chemoresistance through
Keap1-Nrf2 signaling. Hepatology. 63:1914–1927. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Essafi A, Fernández de Mattos S, Hassen
YA, Soeiro I, Mufti GJ, Thomas NS, Medema RH and Lam EW: Direct
transcriptional regulation of Bim by FoxO3a mediates STI571-induced
apoptosis in Bcr-Abl-expressing cells. Oncogene. 24:2317–2329.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fernández de Mattos S, Villalonga P,
Clardy J and Lam EW: FOXO 3a mediates the cytotoxic effects of
cisplatin in colon cancer cells. Mol Cancer Ther. 7:3237–3246.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsai KL, Sun YJ, Huang CY, Yang JY, Hung
MC and Hsiao CD: Crystal structure of the human FOXO3a-DBD/DNA
complex suggests the effects of post-translational modification.
Nucleic Acids Res. 35:6984–6994. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hammond SM: RNAi, microRNAs, and human
disease. Cancer Chemother Pharmacol. 58 Suppl 1:S63–S68. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim VN: MicroRNA biogenesis: Coordinated
cropping and dicing. Nat Rev Mol Cell Biol. 6:376–385. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mohammadi A, Mansoori B and Baradaran B:
The role of microRNAs in colorectal cancer. Biomed Pharmacother.
84:705–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Strubberg AM and Madison BB: MicroRNAs in
the etiology of colorectal cancer: Pathways and clinical
implications. Dis Model Mech. 10:197–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagaraju GP, Madanraj AS, Aliya S, Rajitha
B, Alese OB, Kariali E, Alam A and El-Rayes BF: MicroRNAs as
biomarkers and prospective therapeutic targets in colon and
pancreatic cancers. Tumour Biol. 37:97–104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang P, Bill K, Liu J, Young E, Peng T,
Bolshakov S, Hoffman A, Song Y, Demicco EG, Terrada DL, et al:
miR-155 is a liposarcoma oncogene that targets casein kinase-1α and
enhancees β-catenin signaling. Cancer Res. 72:1751–1762. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Robertson ED, Wasylyk C, Ye T, Jung AC and
Wasylyk B: The oncogenic MicroRNA Hsa-miR-155-5p targets the
transcription factor ELK3 and links it to the hypoxia response.
PLoS One. 9:e1130502014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garzon R, Heaphy CE, Havelange V, Fabbri
M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA,
et al: MicroRNA 29b functions in acute myeloid leukemia. Blood.
114:5331–5341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Costinean S, Zanesi N, Pekarsky Y, Tili E,
Volinia S, Heerema N and Croce CM: Pre-B cell proliferation and
lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155
transgenic mice. Proc Natl Acad Sci USA. 103:pp. 7024–7029. 2006;
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen G, Tang Y, Wu JH and Liu FH: Role of
microRNAs in diagnosis and treatment of the pathogenesis of gastric
cancer. Int J Clin Exp Med. 7:5947–5957. 2014.PubMed/NCBI
|
|
24
|
Saito Y, Suzuki H, Matsuura M, Sato A,
Kasai Y, Yamada K, Saito H and Hibi T: MicroRNAs in hepatobiliary
and pancreatic cancers. Front Genet. 2:662011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Greither T, Grochola LF, Udelnow A,
Lautenschläger C, Würl P and Taubert H: Elevated expression of
microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated
with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kong W, Yang H, He L, Zhao JJ, Coppola D,
Dalton WS and Cheng JQ: MicroRNA-155 is regulated by the
transforming growth factor beta/Smad pathway and contributes to
epithelial cell plasticity by targeting RhoA. Mol Cell Biol.
28:6773–6784. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Neilsen PM, Noll JE, Mattiske S, Bracken
CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ
and Callen DF: Mutant p53 drives invasion in breast tumors through
up-regulation of miR-155. Oncogene. 32:2992–3000. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Willimott S and Wagner SD: miR-125b and
miR-155 contribute to BCL2 repression and proliferation in response
to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem.
287:2608–2617. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang M, Zhang P, Li Y, Liu G, Zhou B, Zhan
L, Zhou Z and Sun X: The quantitative analysis by stem-loop
real-time PCR revealed the microRNA-34a, microRNA-155 and
microRNA-200c overexpression in human colorectal cancer. Med Oncol.
29:3113–3118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kara M, Yumrutas O, Ozcan O, Celik OI,
Bozgeyik E, Bozgeyik I and Tasdemir S: Differential expressions of
cancer-associated genes and their regulatory miRNAs in colorectal
carcinoma. Gene. 567:81–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Renault VM, Thekkat PU, Hoang KL, White
JL, Brady CA, Kenzelmann Broz D, Venturelli OS, Johnson TM, Oskoui
PR, Xuan Z, et al: The pro-longevity gene FoxO3 is a direct target
of the p53 tumor suppressor. Oncogene. 30:3207–3221. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Naito S, von Eschenbach AC, Giavazzi R and
Fidler IJ: Growth and metastasis of tumor cells isolated from a
human renal cell carcinoma implanted into different organs of nude
mice. Cancer Res. 46:4109–4115. 1986.PubMed/NCBI
|
|
34
|
Min M, Peng L, Yang Y, Guo M, Wang W and
Sun G: MicroRNA-155 is involved in the pathogenesis of ulcerative
colitis by targeting FOXO3a. Inflamm Bowel Dis. 20:652–659. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ling N, Gu J, Lei Z, Li M, Zhao J, Zhang
HT and Li X: microRNA-155 regulates cell proliferation and invasion
by targeting FOXO3a in glioma. Oncol Rep. 30:2111–2118. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2010. View Article : Google Scholar
|
|
37
|
Hu XJ, Xie MY, Kluxen FM and Diel P:
Genistein modulates the anti-tumor activity of cisplatin in MCF-7
breast and HT-29 colon cancer cells. Arch Toxicol. 88:625–635.
2014.PubMed/NCBI
|
|
38
|
Serova M, Calvo F, Lokiec F, Koeppel F,
Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E and
Raymond E: Characterizations of irofulven cytotoxicity in
combination with cisplatin and oxaliplatin in human colon, breast,
and ovarian cancer cells. Cancer Chemother Pharmacol. 57:491–499.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lacour S, Micheau O, Hammann A, Drouineaud
V, Tschopp J, Solary E and Dimanche-Boitrel MT: Chemotherapy
enhances TNF-related apoptosis-inducing ligand DISC assembly in
HT29 human colon cancer cells. Oncogene. 22:1807–1816. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Burgering BM: A brief introduction to
FOXOlogy. Oncogene. 27:2258–2262. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Arden KC: FoxO: Linking new signaling
pathways. Mol Cell. 14:416–418. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen Q, Ganapathy S, Singh KP, Shankar S
and Srivastava RK: Resveratrol induces growth arrest and apoptosis
through activation of FOXO transcription factors in prostate cancer
cells. PLoS One. 5:e152882010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Calin GA, Liu CG, Sevignani C, Ferracin M,
Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al:
MicroRNA profiling reveals distinct signatures in B cell chronic
lympho cytic leukemias. Proc Natl Acad Sci USA. 101:pp.
11755–11760. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tili E, Croce C and Michaille J: miR-155:
On the crosstalk between inflammation and cancer. Int Rev Immunol.
28:264–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261.
2006; View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Valeri N, Gasparini P, Fabbri M, Braconi
C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, et
al: Modulation of mismatch repair and genomic stability by miR-155.
Proc Natl Acad Sci USA. 107:pp. 6982–6987. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sandhu SK, Volinia S, Costinean S, Galasso
M, Neinast R, Santhanam R, Parthun MR, Perrotti D, Marcucci G,
Garzon R and Croce CM: miR-155 targets histone deacetylase 4
(HDAC4) and impairs transcrip tional activity of B-cell lymphoma 6
(BCL6) in the Emu-miR-155 transgenic mouse model. Proc Nat Acad Sci
USA. 109:pp. 20047–20052. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li S, Chen T, Zhong Z, Wang Y, Li Y and
Zhao X: microRNA-155 silencing inhibits proliferation and migration
and induces apoptosis by upregulating BACH1 in renal cancer cells.
Mol Med Rep. 5:949–954. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang P, Bill K, Liu J, Young E, Peng T,
Bolshakov S, Hoffman A, Song Y, Demicco EG, Terrada DL, et al:
miR-155 is a liposarcoma oncogene that targets casein kinase-1α and
enhances b-catenin signaling. Cancer Res. 72:1751–1762. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lv L, An X, Li H and Ma L: Effect of
miR-155 knockdown on the reversal of doxorubicin resistance in
human lung cancer A549/dox cells. Oncol Lett. 11:1161–1166. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Vigorito E, Kohlhaas S, Lu D and Leyland
R: miR-155: An ancient regulator of the immune system. Immunol Rev.
253:146–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Higgs G and Slack F: The multiple roles of
microRNA-155 in onco genesis. J Clin Bioinforma. 3:172013.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yu DD, Lv MM, Chen WX, Zhong SL, Zhang XH,
Chen L, Ma TF, Tang JH and Zhao JH: Role of miR-155 in drug
resistance of breast cancer. Tumour Biol. 36:1395–1401. 2015.
View Article : Google Scholar : PubMed/NCBI
|
